Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes

Endocrine Journal
Kumiko TanakaHiroshi Itoh

Abstract

There is little information on direct comparison between metformin and glucagon-like peptide-1 (GLP-1) receptor agonists in the Asian population. This study examined the efficacy and safety of liraglutide monotherapy compared with metformin monotherapy in overweight/obese Japanese patients with type 2 diabetes (T2DM). The study was a 24-week, open-labeled, randomized controlled study. Overweight or obese patients with T2DM aged 20-75 years with suboptimal glycemic control were randomized to liraglutide or metformin monotherapy. The primary endpoint was change in HbA1c at week 24. Secondary endpoints included changes in daily glycemic profile, body weight, incidence of hypoglycemia and other adverse events. The study, which was originally planned to enroll 50 subjects in each group, was ended with insufficient recruitment. A total of 46 subjects completed the study, and analysis was conducted in this cohort. Reduction in HbA1c at week 24 was comparable between the metformin (n = 24) and liraglutide (n = 22) groups (-0.95 ± 0.80% vs. -0.80 ± 0.88%, p = 0.77), while the liraglutide group reached maximal reduction more rapidly than did the metformin group. There was no significant difference in weight gain or incidence of hypoglyce...Continue Reading

References

Dec 1, 1991·The Journal of Clinical Endocrinology and Metabolism·R A DeFronzoD C Simonson
Jan 17, 2008·The Journal of Clinical Endocrinology and Metabolism·Katherine EspositoDario Giugliano
Feb 12, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·M DaviesR Cuddihy
Mar 4, 2011·The New England Journal of Medicine·Sreenivasa Rao Kondapally SeshasaiUNKNOWN Emerging Risk Factors Collaboration
May 23, 2012·Clinical Therapeutics·Vanita R ArodaByron J Hoogwerf
Sep 5, 2012·Nature Reviews. Endocrinology·Juris J Meier
Apr 20, 2013·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberUNKNOWN American Association of Clinical Endocrinologists
Dec 4, 2013·Annals of Internal Medicine·Caroline K KramerRavi Retnakaran
Jan 17, 2014·The New England Journal of Medicine·Deirdre K TobiasFrank B Hu
Feb 11, 2014·Diabetes Research and Clinical Practice
Nov 14, 2014·The Journal of Clinical Endocrinology and Metabolism·Manfredi RizzoGiovanni Li Volti

❮ Previous
Next ❯

Citations

Mar 10, 2017·Physiological Reviews·T D MüllerM H Tschöp
Sep 1, 2017·The Journal of Endocrinology·Guillaume MabilleauChantal Chenu
Sep 14, 2019·Journal of Diabetes Investigation·Yuusuke WatanabeUNKNOWN Twin-exenatide Study Group
Nov 27, 2019·Molecular Metabolism·T D MüllerM H Tschöp
Nov 13, 2020·Frontiers in Pharmacology·Guadalupe Del Carmen Baeza-FloresVinicio Granados-Soto
Sep 16, 2021·Journal of Obesity & Metabolic Syndrome·Jared RosenbergJoon Young Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.